Supplemental Table: Adverse events during the study

Adverse Event Category	Occurrences per Aggregate Year (Month 1 to Month 6)			P-value[2]
	Placebo N = 165	ALA & Vit E N = 160	All N = 325	
GI upset	0.73	1.27	0.99	0.002
infection	0.94	0.76	0.85	0.287
access related	0.44	0.79	0.61	0.011
cardiac	0.47	0.53	0.50	0.619
other	0.51	0.35	0.43	0.161
pain	0.45	0.38	0.42	0.527
pulmonary	0.32	0.48	0.40	0.157
viral infection	0.42	0.33	0.38	0.395
neurological	0.20	0.18	0.19	0.772
hypertension/hypotension	0.20	0.13	0.17	0.326
diabetes	0.15	0.12	0.13	0.637
dizziness	0.18	0.07	0.12	0.092
musculoskeletal	0.12	0.10	0.11	0.762
allergy	0.09	0.13	0.11	0.446
edema	0.09	0.13	0.11	0.446
electrolyte disorder	0.03	0.17	0.09	0.025
generalized symptoms	0.09	0.10	0.09	0.829
fluid overload	0.15	0.02	0.09	0.038
anemia	0.03	0.10	0.06	0.134
trauma	0.06	0.07	0.06	0.860
eye related	0.01	0.07	0.04	0.177
lesions	0.01	0.05	0.03	0.290
Overall Rate	5.16	6.11	5.60	0.023

[2] Determined using Pearson test